Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax
9.12.2024 12:00:00 CET | Business Wire | Press release
Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status.
We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standard VEN therapy (first-line therapy). Additionally, the bone marrow cell count in peripheral blood in all three cases was 0 (zero) within 4 (four) weeks of starting treatment, and complete remission (CR or CRi) was confirmed by subsequent bone marrow biopsy.
Three more patients will be added at the current dosage regimen, and after confirmation of the tolerability, the study will move to Phase II. Complete remission has been observed in patients who have failed/relapsed after existing VEN combination therapy (first-line therapy), so this is expected to be a new, highly effective second-line therapy for patients with AML.
As previously reported, the data cleaning processes for interim analysis are currently underway for Phase III comparative clinical trial (150 cases) of DFP-10917 monotherapy targeting patients with AML receiving third-line or later therapy. Once this is completed, the results will be submitted to the Independent Data Safety Monitoring Committee (DSMB) along with electrocardiogram and pharmacokinetic study results for their advice.
Please take notice of our own innovative approach for miserable cancer patients and contact us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209579716/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perion's AI Agent Outmax Now Available for TikTok, Delivering Up to 25% Greater Media Performance in Early Results10.3.2026 12:00:00 CET | Press release
Perion's extension into one of the fastest-growing advertising platforms represents a big leap in TAM expansion, as TikTok Ad Revenue is expected to exceed $50 billion by 2027 Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today announced the launch of its proprietary Outmax AI agent for TikTok. This integration extends Perion’s capabilities to one of the fastest-growing global advertising platforms, with nearly 1.6 billion users worldwide and rapidly expanding advertiser adoption as brands increasingly prioritize TikTok in their media strategies. TikTok’s advertising revenue is expected to exceed $50 billion by 20271. Perion’s Outmax AI agent is embedded within Perion’s AI-native infrastructure, designed to increase advertiser efficiency and performance. Fully integrated with TikTok, Outmax applies algorithmic intelligence beyond native platform defaults, enablin
The KCAS Bio – Lyon, France Site Renews Its GLP Compliance Statement, Strengthening Its Support for IND-Enabling Studies Through Bioanalysis and Biomarkers10.3.2026 12:00:00 CET | Press release
KCAS Bio today announced that its European site in Lyon, France, has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP) according to Directive 2004/9/CE (safety tests), confirming the site’s continued ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. The GLP test facility once again earned a Level of Compliance “A,” reinforcing KCAS Bio’s capability to support critical investigational new drug (IND)-enabling programs. This renewal provides sponsors with continued confidence that their studies are supported by robust, compliant, and regulatory-ready bioanalytical data. This GLP renewal, combined with the site's ISO 9001:2015 certification, which has been maintained without interruption for more than 15 years, reflects the rigor, reliability, and consistency demonstrated by the scientific teams at the Lyon site in all projects throughout the drug discovery and development continuum. “Our renewed GLP compliance undersc
Reply: a New Study Shows that Agentic AI will Become a Strategic Alternative to Traditional Sourcing Models for 93% of Tech Leaders10.3.2026 11:26:00 CET | Press release
Reply [EXM, STAR: REY] today announced the release of “From Code to Control: AI’s Takeover of Software Development Lifecycle”, a commissioned study conducted by Forrester Consulting. The research, which surveyed 536 IT Executives across Europe and the US, highlights the progressive transition from simple AI coding assistants to autonomous agents capable of orchestrating the entire software development lifecycle (SDLC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310922600/en/ Silicon Shoring is Reply’s delivery model designed to leverage this shift toward Agentic AI. By using the Silicon Reply multi-agent system, this methodology offers a robust alternative to traditional offshoring. The study underscores a critical turning point for software development: as traditional offshoring models struggle with hidden costs and regulatory hurdles, 93% of organisations plan to adopt Agentic AI within the next two to three years a
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel10.3.2026 11:00:00 CET | Press release
WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310966566/en/ WHOOP Broadens WHOOP Adva
Spring into Smarter Home Protection: EZVIZ Launches Standout Deals for the Amazon Spring Sale10.3.2026 10:30:00 CET | Press release
As the new season brings longer days and fresh beginnings, EZVIZ is turning up the excitement with a lineup of irresistible offers during the Amazon Spring Sale. Known for delivering easy-to-use smart security products, EZVIZ is giving households the perfect opportunity to refresh their home protection with technology designed for modern living. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310567932/en/ Spring into smarter home protection: EZVIZ launches standout deals for the Amazon Spring Sale As homes open up to the energy of spring, whether welcoming guests, receiving more deliveries, or simply spending more time outdoors, this seasonal sales on Amazon offers a timely chance to upgrade everyday security. During the Spring Sale, shoppers can enjoy limited-time savings on a curated selection of EZVIZ’s smart cameras and entryway products, making it easier to safeguard front doors, gardens, and outdoor spaces while emb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom